Skip to main content
Lupin acquires Symbiomix Therapeutics

Lupin purchased Symbiomix Therapeutics and gained rights to Symbiomix's newly approved Solosec, or secnidazole, which is intended for launch by mid-2018, for the treatment of bacterial vaginosis. Symbiomix will receive $50 million upfront and another $100 million for future milestones and contingent payments.

Full Story: